RxDoctor Payments Data

Paul Haver, MD

Family Medicine · Athens, GANPI 1770578155

Payments from drug & device makers

$8,851in general payments, 2019–2025

Across 567 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$877
  • Lilly USA, LLC$748
  • Amgen$526
  • Boehringer Ingelheim$513
  • Pfizer$498
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,77199%
  • Education$210%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,851 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$122,477
Medicare patients
226
Services billed
1,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$116,520
EliquisApixaban94$79,825
MounjaroTirzepatide50$61,199
JardianceEmpagliflozin59$52,135
TrulicityDulaglutide22$33,406
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,894
Soliqua 100-33Insulin Glargine/Lixisenatide21$25,706
XareltoRivaroxaban14$21,598
RexultiBrexpiprazole13$18,317
WegovySemaglutide12$15,744
FarxigaDapagliflozin Propanediol24$14,113
Tresiba Flextouch U-200Insulin Degludec22$8,908
Janumet XrSitagliptin Phos/Metformin Hcl14$8,013
TradjentaLinagliptin14$6,943
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,248$132,264127 claims
Lilly USA, LLCMounjaro, Trulicity$748$94,60572 claims
PfizerEliquis$498$79,82594 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$513$64,52784 claims
GSKTrelegy Ellipta$440$26,89436 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$180$25,70621 claims
Johnson & JohnsonXarelto$153$21,59814 claims
Otsuka America Pharmaceutical, Inc.Rexulti$189$18,31713 claims
AstraZenecaFarxiga$877$14,11324 claims
MerckJanumet Xr$42$8,01314 claims
AbbVieSynthroid$492$2,06731 claims
Scilex Pharmaceuticals Inc.Colchicine$37$1,43335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →